Since 2000, he has focused his research program on the genetic basis of peripheral myelination and the disruptions found in peripheral neuropathies such as CMT. Dr. Svaren is working with the CMTA to lead one arm of the collaboraive STAR project, which is focused on understanding the regulation of the PMP22 gene in order to develop novel assays for drug screening at the NIH. Although his primary focus has been on CMT1A, he welcomes the opportunity to help develop and implement a multi-front strategy directed at other forms of CMT.